<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>&lt;i&gt;Clostridioides difficile&lt;/i&gt; infection in children: Treatment and outcome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center"><i>Clostridioides difficile</i> infection in children: Treatment and outcome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle"><i>Clostridioides difficile</i> infection in children: Treatment and outcome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Crews, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maribeth R Nicholson, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Clostridioides</em> <em>difficile</em> is an important cause of antibiotic-associated diarrhea and one of the most common health care-associated pathogens [<a href="#rid1">1</a>]. Its clinical manifestations range from asymptomatic colonization or mild diarrhea to fulminant disease characterized by ileus, toxic megacolon, hypotension, or shock. <em>C. difficile</em> infection is less common in children than adults, but the incidence of <em>C. difficile</em> infection in children is increasing [<a href="#rid2">2-5</a>].</p><p>The treatment of and outcomes associated with <em>C. difficile</em> infection in children will be discussed here. The pathogenesis, epidemiology, clinical features, diagnosis, and prevention of <em>C. difficile</em> in children and <em>C. difficile</em> in adults are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6041.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Microbiology, pathogenesis, and epidemiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2687.html" rel="external">"<i>Clostridioides difficile</i> infection: Prevention and control"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a>.)</p><p></p><p>There is limited high-quality evidence to guide the management of <em>C. difficile</em> infection in children. Most treatment recommendations are extrapolated from studies performed in adults. The treatment guidelines presented below are largely compatible with the recommendations of the American Academy of Pediatrics Committee on Infectious Diseases (2021) [<a href="#rid6">6</a>], the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.idsociety.org%2Fpractice-guideline%2Fclostridium-difficile%2F&amp;token=FtdgY9LPBjngqfa3%2FrNgHlj%2BDpae1o%2F4xMzNDH6KNvsSNskRppha1ovBvqTMkoOpBuoHdPjNMBOmr5QVgNWOSlJvxWnn5%2FQ7hA0pZxgGW2o%3D&amp;TOPIC_ID=6050" target="_blank">Infectious Diseases Society of America and Society for Healthcare Epidemiology of America</a> (2017) [<a href="#rid7">7</a>], and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgi.org%2Fguidelines%2F&amp;token=Og4ss9xZ8giAwuAeSJ0YNc6skx84OvXZrMgtpdmNxqc7PB%2F4DeCjmena7knDpUfp&amp;TOPIC_ID=6050" target="_blank">the American College of Gastroenterology</a> (2021) [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H6"><span class="h1">GENERAL MEASURES</span></p><p class="headingAnchor" id="H7"><span class="h2">Discontinuation of inciting antibiotics</span><span class="headingEndMark"> — </span>Discontinuation of the inciting antibiotic, when possible, is important in the management of <em>C. difficile </em>infection [<a href="#rid6">6,7,9</a>]. The use of concomitant antibiotics (ie, antibiotics other than those used to treat <em>C. difficile</em>) during treatment for <em>C. difficile</em> infection has been shown to prolong the duration of symptoms and increase the risk of recurrence in adults [<a href="#rid10">10</a>]. In children, the use of concomitant antibiotics has been associated with recurrent disease [<a href="#rid11">11</a>]. If an ongoing infection requires continued antibiotic treatment, we suggest modifying therapy to achieve the narrowest spectrum and shortest duration possible. (See  <a class="medical medical_review" href="/d/html/6041.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Microbiology, pathogenesis, and epidemiology", section on 'Antibiotic exposure'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Supportive care for children with diarrhea from <em>C. difficile</em> includes correction of fluid losses and electrolyte imbalances [<a href="#rid9">9,12</a>]. (See  <a class="medical medical_review" href="/d/html/6142.html" rel="external">"Clinical assessment of hypovolemia (dehydration) in children"</a> and  <a class="medical medical_review" href="/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a>.)</p><p>Antimotility drugs (eg, <a class="drug drug_pediatric" data-topicid="12561" href="/d/drug information/12561.html" rel="external">loperamide</a>) and opioids are discouraged due to concerns they may delay clearance of toxins and predispose to complications such as ileus or toxic megacolon, although this association has not been observed in clinical studies [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H2248420511"><span class="h2">Indications for hospitalization</span><span class="headingEndMark"> — </span>Children with fulminant disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>) should be hospitalized. Hospitalization may be warranted for children with dehydration, electrolyte abnormalities, moderate to marked toxicity, or severe disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>). Recommendations for the prevention of <em>C. difficile</em> infection in hospital settings are discussed separately. (See  <a class="medical medical_review" href="/d/html/2687.html" rel="external">"<i>Clostridioides difficile</i> infection: Prevention and control", section on 'Prevention strategies'</a>.)</p><p>Consultation with specialists in infectious diseases, gastrointestinal disease, and/or surgery may be warranted for children with severe or fulminant disease.</p><p class="headingAnchor" id="H3116939453"><span class="h2">Indications for antimicrobial therapy</span><span class="headingEndMark"> — </span>We initiate antimicrobial therapy in children with symptomatic <em>C. difficile</em> infection (<a class="graphic graphic_table graphicRef71790" href="/d/graphic/71790.html" rel="external">table 2</a>) [<a href="#rid6">6,7</a>]. The antimicrobial regimen depends upon the severity of disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>). (See <a class="local">'Mild or moderate disease'</a> below and <a class="local">'Severe disease'</a> below and <a class="local">'Fulminant disease'</a> below.)</p><p>Empiric antimicrobial therapy, pending results of <em>C. difficile</em> testing, is not routinely recommended but may be warranted if there is a delay in laboratory confirmation or for severe or fulminant disease (<a class="graphic graphic_table graphicRef71790" href="/d/graphic/71790.html" rel="external">table 2</a>) [<a href="#rid7">7,14</a>].</p><p>Antimicrobial therapy is <strong>not</strong> indicated in children with asymptomatic colonization with <em>C. difficile</em> [<a href="#rid6">6,7</a>]. In a randomized trial of asymptomatic adults colonized with <em>C. difficile</em>, treatment with <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> had no effect on colonization status. Treatment with <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, while temporarily effective in eradicating detectable colonization, was associated with increased rates of carriage two months after therapy [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3590946801"><span class="h1">ANTIMICROBIAL THERAPY FOR INITIAL EPISODE</span></p><p class="headingAnchor" id="H100909150"><span class="h2">Mild or moderate disease</span><span class="headingEndMark"> — </span>The majority of children with <em>C. difficile</em> infection have mild to moderate disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>). Inciting antibiotics should be discontinued if possible and supportive measures provided as indicated. (See <a class="local">'General measures'</a> above.)</p><p>For the initial episode of <em>C. difficile</em> infection in children and adolescents with mild or moderate disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>), we suggest treatment with oral <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a>, or <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">fidaxomicin</a> (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>) [<a href="#rid6">6,7,16</a>]. Although most published guidelines only include vancomycin or metronidazole for mild to moderate nonrecurrent <em>C. difficile </em>infection in children, the US Food and Drug Administration approved the use of fidaxomicin for <em>C. difficile </em>infection in children in 2020.</p><p>The regimens are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> 40 mg/kg per day orally in four divided doses (maximum 125 mg/dose) for 10 days, <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">Metronidazole</a> 30 mg/kg per day orally in four divided doses (maximum 500 mg/dose) for 10 days, <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">Fidaxomicin</a> is dosed according to body weight as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>4 to &lt;7 kg (oral suspension) – 80 mg orally twice daily for 10 days</p><p class="bulletIndent2"><span class="glyph">•</span>7 to &lt;9 kg (oral suspension) – 120 mg orally twice daily for 10 days</p><p class="bulletIndent2"><span class="glyph">•</span>9 to &lt;12.5 kg (oral suspension) – 160 mg orally twice daily for 10 days</p><p class="bulletIndent2"><span class="glyph">•</span>≥12.5 kg (oral suspension or tablets) – 200 mg orally twice daily for 10 days</p><p></p><p>Prospective studies comparing <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> and <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> for the treatment of <em>C. difficile</em> infection in children are lacking. Accumulated experience suggests that children with <em>C. difficile</em> infection have good outcomes, including similar rates of recurrence, with either oral metronidazole or vancomycin [<a href="#rid7">7,17-19</a>]. In a meta-analysis of seven retrospective observational studies (pooled total of 433 cases), cure rates were higher with vancomycin; however, this was not statistically significant (odds ratio 0.63, 95% CI 0.36-1.10) [<a href="#rid20">20</a>].</p><p>Randomized trials including adult patients have found <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> to be superior to <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> [<a href="#rid7">7,21,22</a>]. In a 2017 meta-analysis of four randomized trials including 872 adult patients with nonsevere <em>C. difficile</em> infection [<a href="#rid21">21-24</a>], vancomycin was slightly more effective than metronidazole at achieving symptomatic cure without recurrence (79 versus 72 percent, risk ratio 0.90, 95% CI 0.84-0.97) [<a href="#rid25">25</a>].</p><p><a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">Fidaxomicin</a> and <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> for the treatment of <em>C. difficile</em> infection in children (initial or recurrent) were compared in a randomized trial in 142 children [<a href="#rid26">26</a>]. Clinical response rates at 12 days were similar (77.6 versus 70.5 percent, adjusted difference 7.5 percent [95% CI -7.4 to 23.9]). However, the rate of recurrence in the 30 days after completion of therapy was lower with fidaxomicin (11.8 versus 29.0 percent; adjusted difference -15.8 [95% CI -34.5 to 0.5]). In pooled analysis of four randomized control trials comparing fidaxomicin and vancomycin (standard dose) in adults, fidaxomicin increased sustained response of <em>C. difficile</em> infection after completion of therapy [<a href="#rid27">27</a>].</p><p>Other considerations when choosing between these drugs are provided below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vancomycin</strong> – <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> use is limited by its greater cost and concerns for promoting the intestinal carriage of vancomycin-resistant enterococci (VRE). However, the risk of subsequent intestinal colonization with VRE appears to be similar with vancomycin and <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> achieves very high fecal concentrations when administered orally because it is not absorbed. It maintains high concentrations throughout the duration of treatment [<a href="#rid15">15</a>]. The oral formulation of vancomycin is more expensive than <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a>; thus, some hospitals use the generic intravenous (IV) formulation for oral administration [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metronidazole</strong> – <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">Metronidazole</a> is not labeled for the treatment of <em>C. difficile</em> infection in children. It is less expensive than <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> [<a href="#rid7">7</a>]. The risk of intestinal colonization with VRE appears to be similar with metronidazole and vancomycin [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">Metronidazole</a> is rapidly absorbed when administered orally; effective fecal concentrations are achieved through biliary excretion and secretion across inflamed intestinal mucosa. Fecal concentrations peak early in illness and decline as symptoms improve [<a href="#rid29">29</a>]. Metronidazole is undetectable in the stool of asymptomatic carriers [<a href="#rid15">15</a>]. <em>C. difficile</em> strains with decreased susceptibility to metronidazole are rare [<a href="#rid30">30-32</a>]. The use of metronidazole is limited by its metallic taste and side effects, primarily nausea and peripheral neuropathy (associated with prolonged administration or cumulative exposure).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fidaxomicin</strong><strong> </strong>– <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">Fidaxomicin</a> is a macrolide antibiotic that has little gastrointestinal absorption [<a href="#rid33">33,34</a>]. It appears to be safe and effective in children, but data are limited [<a href="#rid26">26</a>]. Fidaxomicin is orally administered with minimal systemic absorption and highly active against<em> C. difficile</em> in vitro. It is also a "narrow spectrum" agent with more limited activity against enteric commensal bacteria than either <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> or <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>. Use is limited by higher cost [<a href="#rid27">27</a>]. In the United States, fidaxomicin is available for the treatment of <em>C. difficile</em>-associated diarrhea in people ≥6 months of age [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H2248421210"><span class="h2">Severe disease</span><span class="headingEndMark"> — </span>For the initial episode of <em>C. difficile</em> infection in children and adolescents with severe<em> </em>disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>), we suggest treatment with oral <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> rather than other agents (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> 40 mg/kg per day orally in four divided doses (maximum 125 mg/dose)</p><p></p><p class="bulletIndent1">The standard duration of treatment for <em>C. difficile</em> infection is 10 days, though the course should be tailored to clinical response.</p><p></p><p>We prefer <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> to <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> for severe disease because of the increased risk of treatment failure with metronidazole in randomized and observational studies of adult patients [<a href="#rid21">21,35-38</a>].</p><p>We prefer <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> to <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">fidaxomicin</a> for severe disease in children because we have greater clinical experience with vancomycin in children. However, for patients ≥18 years of age, expert groups suggest either fidaxomicin or vancomycin [<a href="#rid8">8,27</a>]. (See  <a class="medical medical_review" href="/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention", section on 'Severe disease'</a>.)</p><p class="headingAnchor" id="H315875231"><span class="h2">Fulminant disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulminant disease in children who can tolerate oral therapy</strong> – For the initial episode of <em>C. difficile</em> infection in children and adolescents with fulminant disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>) who can tolerate oral therapy, we suggest treatment with the combination of IV <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> and oral <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">Metronidazole</a> 30 mg/kg per day in three divided doses (maximum 500 mg/dose) for 10 days, <strong>plus</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> 40 mg/kg per day by mouth in four divided doses (maximum 500 mg/dose until clinical improvement and then, if applicable, decrease the maximum dose to 125 mg to complete 10 days)</p><p></p><p class="bulletIndent1">Although the standard duration of treatment for <em>C. difficile</em> infection is 10 days, the course should be tailored to clinical response.</p><p></p><p class="bulletIndent1">We obtain serum <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> levels in children with fulminant disease who are receiving high-dose vancomycin (maximum 500 mg/dose) because systemic absorption can occur in patients with severe colitis [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">Using an increased maximum dose of <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> for children with fulminant disease is suggested in the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America clinical practice guidelines for <em>C. difficile</em> infection in adults and children [<a href="#rid7">7</a>]. However, there are limited data to support the efficacy of this approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulminant disease in children who cannot tolerate oral therapy</strong> – For the initial episode of <em>C. difficile</em> infection in children and adolescents with fulminant disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>) who cannot tolerate oral therapy (eg, ileus, toxic megacolon), we suggest treatment with the combination of IV <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> and rectal <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>). Biliary and intestinal excretion of parenteral metronidazole achieve therapeutic concentrations of metronidazole in the stool [<a href="#rid29">29</a>]. Rectal vancomycin is added because monotherapy with IV metronidazole is less effective than oral metronidazole or oral vancomycin [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">We use the following regimen:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">Metronidazole</a> 30 mg/kg per day in three divided doses (maximum 500 mg/dose) for 10 days, <strong>plus</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> 10 mg/kg per dose in normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (maximum dose 500 mg in 100 mL normal saline) administered by retention enema four times per day for 10 days; the volume of solution varies with age [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>1 through 4 years – 50 mL</p><p class="bulletIndent3"><span class="glyph">-</span>5 through 11 years – 75 mL</p><p class="bulletIndent3"><span class="glyph">-</span>≥12 years – 100 mL</p><p></p><p class="bulletIndent1">Although the standard duration of treatment for <em>C. difficile</em> infection is 10 days, the course should be tailored to clinical response.</p><p></p><p class="bulletIndent1">The optimal dose and volume for rectal <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> has not been established for children or adults; the dose used in published case series varies widely [<a href="#rid41">41</a>]. Dose and volume adjustments may be required depending upon individual circumstances, extent of colonic disease, and patient weight. Caution is required because perforation is possible with rectal installation of vancomycin.</p><p></p><p class="bulletIndent1">We obtain serum <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> levels in children with fulminant disease who are receiving vancomycin via retention enema because systemic absorption can occur in patients with severe colitis [<a href="#rid39">39</a>].</p><p></p><p class="headingAnchor" id="H344215800"><span class="h1">SURGICAL THERAPY FOR FULMINANT DISEASE</span><span class="headingEndMark"> — </span>Surgery (ie, subtotal colectomy, diversion ileostomy) may be required as a life-saving measure for severely ill children with toxic megacolon, colonic perforation, acute abdomen, or septic shock. The indications for surgery in children with fulminant disease from <em>C. difficile</em> infection are not well established. Subtotal or total colectomy is most often performed, although colon-sparing surgical techniques have been described [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H13"><span class="h1">RESPONSE TO TREATMENT</span><span class="headingEndMark"> — </span>The response to treatment of <em>C. difficile</em> infection is assessed clinically. In patients with mild to moderate disease, symptoms generally improve within 48 to 72 hours after initiation of antibiotic therapy, but diarrhea may not fully resolve for four to five days [<a href="#rid12">12,44</a>]. Responses may be slower with <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> or with infection from the NAP1/BI/027 strain [<a href="#rid45">45,46</a>].</p><p>Follow-up testing for <em>C. difficile</em> is <strong>not</strong> recommended because patients can remain colonized with toxin-producing strains after recovery [<a href="#rid6">6</a>].</p><p>Patients remain vulnerable to recurrence of <em>C. difficile</em> infection for up to eight weeks (or longer) following treatment [<a href="#rid47">47</a>]. A recurrence of gastrointestinal symptoms requires evaluation. (See <a class="local">'Management of recurrence'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h1">MANAGEMENT OF TREATMENT FAILURE</span><span class="headingEndMark"> — </span>Treatment failure is defined as progression of disease or failure to improve after several days of therapy [<a href="#rid12">12</a>]. A minority of children with <em>C. difficile</em> infection fail to respond to treatment [<a href="#rid18">18,48,49</a>].</p><p>Among children with <em>C. difficile</em> infection and ongoing symptoms despite treatment, a proportion will have underlying gastrointestinal disorders [<a href="#rid18">18</a>]. Ongoing symptoms can also be caused by coinfection with an additional enteric pathogen. Children with progression of disease or failure to improve after three to four days of antibiotic therapy should be evaluated (or reevaluated) for other causes of diarrhea. The possibility of an underlying predisposing condition must also be considered. (See  <a class="medical medical_review" href="/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6041.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Microbiology, pathogenesis, and epidemiology", section on 'Predisposing conditions'</a>.)</p><p>The optimal management of refractory <em>C. difficile</em> infection in children is not established. If another etiology cannot be identified, we suggest discontinuing the inciting antibiotic (if this has not already occurred) and switching to <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> or <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">fidaxomicin</a> in patients that fail to respond to treatment with <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a>. For children who fail initial treatment with vancomycin or fidaxomicin, we evaluate for other causes of diarrhea.</p><p class="headingAnchor" id="H36637750"><span class="h1">MANAGEMENT OF RECURRENCE</span><span class="headingEndMark"> — </span>Recurrent <em>C. difficile</em> infection is a return of symptoms with a positive assay result after a period of symptom resolution that occurs within eight weeks of the initial episode (typically within one to three weeks) [<a href="#rid7">7,50,51</a>]. (See  <a class="medical medical_review" href="/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis", section on 'Recurrent infection'</a>.)</p><p class="headingAnchor" id="H3116940015"><span class="h2">First recurrence</span><span class="headingEndMark"> — </span>The signs and symptoms of recurrence are similar to those in the initial episode. Investigation for other causes of diarrhea may be warranted because a return of diarrhea is not always due to a recurrence of <em>C. difficile</em> infection<em>.</em> Since persistence of <em>C. difficile</em> is common after effective treatment, a positive <em>C. difficile</em> test may represent colonization.</p><p>For children with a first recurrence, a second course of treatment with the same antibiotic (either <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a>, or <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">fidaxomicin</a>) is suggested (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>) [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H3116940022"><span class="h2">Subsequent recurrences</span><span class="headingEndMark"> — </span>The optimal management of multiple recurrence of <em>C. difficile</em> infection is not established and clinical practice varies [<a href="#rid52">52</a>]. <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">Metronidazole</a> is not recommended for the treatment of a second (or subsequent) recurrence or for prolonged therapy due to the risk of neurotoxicity [<a href="#rid6">6</a>].</p><p>Among the available options for treatment of subsequent recurrences of <em>C. difficile</em> infection in children, we suggest either oral <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> given in a pulsed-tapered fashion or <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">fidaxomicin</a> (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>). Both of these options appear to be safe and effective, but data in children are limited.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulse-tapered </strong><strong>vancomycin</strong> – We use the following regimen for pulse-tapered <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> [<a href="#rid7">7,53-55</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>10 mg/kg (maximum 125 mg/dose) four times daily for 10 to 14 days, followed by</p><p class="bulletIndent2"><span class="glyph">•</span>10 mg/kg (maximum 125 mg/dose) twice daily for 7 days, followed by</p><p class="bulletIndent2"><span class="glyph">•</span>10 mg/kg (maximum 125 mg/dose) once daily for 7 days, followed by</p><p class="bulletIndent2"><span class="glyph">•</span>10 mg/kg (maximum 125 mg/dose) every other day for 7 days, followed by</p><p class="bulletIndent2"><span class="glyph">•</span>10 mg/kg (maximum 125 mg/dose) every 3 days for 2 to 8 weeks</p><p></p><p class="bulletIndent1">In an observational study, taper regimens that were completed with every-three-days dosing were associated with higher cure rates than regimens that ended with every-other-day dosing (81 versus 61 percent) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1">Pulse-tapered <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> has been successful in clinical trials in adult patients, including a small randomized trial [<a href="#rid54">54,56</a>], and has been used in adults and children with multiple recurrences of <em>C. difficile</em> infection [<a href="#rid7">7,52,55</a>]. For patients with subsequent recurrence, previous treatment with pulse-tapered vancomycin also may be associated with a decreased risk of failure of fecal microbiota transplantation (FMT) [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fidaxomicin</strong> – <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">Fidaxomicin</a> is dosed according to body weight as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>4 to &lt;7 kg (oral suspension) – 80 mg orally twice daily for 10 days</p><p class="bulletIndent2"><span class="glyph">•</span>7 to &lt;9 kg (oral suspension) – 120 mg orally twice daily for 10 days</p><p class="bulletIndent2"><span class="glyph">•</span>9 to &lt;12.5 kg (oral suspension) – 160 mg orally twice daily for 10 days</p><p class="bulletIndent2"><span class="glyph">•</span>≥12.5 kg (oral suspension or tablets) – 200 mg orally twice daily for 10 days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive </strong><strong>bezlotoxumab</strong><strong> –</strong> For patients ≥1 year of age with subsequent recurrence within six months of the previous episode and risk factors for recurrent <em>C. difficile inf</em>ection (eg, immunocompromised host), adjunctive treatment with a single dose of <a class="drug drug_pediatric" data-topicid="141999" href="/d/drug information/141999.html" rel="external">bezlotoxumab</a> 10 mg/kg intravenously during administration of standard-of-care antibiotics (eg, <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">fidaxomicin</a>) may prevent subsequent recurrences [<a href="#rid27">27</a>]. Bezlotoxumab is given as a 60-minute intravenous infusion at any time before completing antibacterial treatment. It should be given with caution in patients with heart failure. (See  <a class="medical medical_review" href="/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention", section on 'Recurrent episode'</a>.)</p><p></p><p class="bulletIndent1">We use <a class="drug drug_pediatric" data-topicid="141999" href="/d/drug information/141999.html" rel="external">bezlotoxumab</a> for patients who are ≥18 years and have immunocompromising conditions or require frequent antibiotics. In younger patients, it is not approved by the US Food and Drug Administration, is expensive, and is not routinely covered by insurance.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="141999" href="/d/drug information/141999.html" rel="external">Bezlotoxumab</a> is a humanized monoclonal antibody against toxin B. In 2016, it was approved by the FDA for the prevention of <em>C. difficile </em>infection in high-risk adults who are receiving standard-of-care antibiotics (eg, <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">fidaxomicin</a>). In two randomized trials in 2655 adult patients, the addition of bezlotoxumab to standard-of-care antibiotics reduced the rate of recurrent <em>C. difficile</em> infection (16 to 17 percent versus 26 to 28 percent) [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">The safety, pharmacokinetics, and efficacy of <a class="drug drug_pediatric" data-topicid="141999" href="/d/drug information/141999.html" rel="external">bezlotoxumab</a> were studied in a randomized trial of 148 children age 1 to &lt;18 years with a current <em>C. difficile </em>infection [<a href="#rid59">59</a>]. Children receiving bezlotoxumab had similar rates of adverse events as those in the placebo group, and no patient discontinued treatment due to an adverse event. Rates of recurrent <em>C. difficile </em>infection were not significantly better compared with placebo (11.2 versus 14.7 percent), although there were too few events to detect a statistical difference.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other options </strong>– Other options for the treatment of subsequent recurrences in children and adolescents include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rifaximin</strong> – <a class="drug drug_pediatric" data-topicid="94528" href="/d/drug information/94528.html" rel="external">Rifaximin</a> is a nonabsorbable, broad-spectrum, rifamycin antibiotic with a good safety profile, minimal drug interactions, and high activity against most strains of <em>C. difficile</em> [<a href="#rid60">60</a>]. A course of rifaximin following standard treatment for <em>C. difficile</em> ("rifaximin chaser") was associated with eradication of infection and decreased rates of relapse [<a href="#rid61">61,62</a>]. Rifaximin is approved in the United States for treatment of travelers' diarrhea in individuals ≥12 years of age; it has additional indications in other countries. Previous treatment with a rifamycin increases the risk of rifaximin resistance in the infecting strain of <em>C. difficile</em>. Rifaximin also has the potential to induce resistance to rifamycins [<a href="#rid63">63,64</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nitazoxanide</strong> – <a class="drug drug_pediatric" data-topicid="12904" href="/d/drug information/12904.html" rel="external">Nitazoxanide</a> is available for the treatment of diarrhea from <em>Cryptosporidium </em>and <em>Giardia </em>in patients ≥1 year of age. It is broadly active against most anaerobic bacteria [<a href="#rid65">65</a>]. In randomized trials, nitazoxanide produced cure and relapse rates similar to <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> and <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> for initial treatment of <em>C. difficile</em> infection [<a href="#rid66">66,67</a>]. Adult patients unresponsive to, or relapsing after, metronidazole treatment had a 66 percent response to one or more courses of nitazoxanide 500 mg twice per day [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Teicoplanin</strong> – Teicoplanin is a glycopeptide antibiotic (similar to <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>) that is inexpensive and available in some countries for the treatment of gram-positive organisms. It is not available in the United States. Teicoplanin appears to be at least as efficacious as vancomycin with fewer adverse effects [<a href="#rid23">23,25</a>].</p><p></p><p class="bulletIndent2">There are limited data on the use of teicoplanin in children with <em>C. difficile</em> infection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fecal microbiota transplantation</strong> – FMT is a procedure in which fecal matter obtained from a healthy donor is administered to a recipient. Several routes of administration have been described, including nasogastric/jejunal tubes, enema, colonoscopy, and oral capsules [<a href="#rid69">69</a>]. Randomized and observational studies have found FMT to be effective in the treatment of recurrent <em>C. difficile</em> infection in adults.</p><p></p><p class="bulletIndent2">In a retrospective multicenter study, 81 percent (271 of 335) of children with recurrent<em> C. difficile</em> infection were cured with a single FMT [<a href="#rid70">70</a>]. Factors associated with increased odds of success included lack of feeding tube, receipt of fresh donor stool (versus thawed, previously frozen stool), delivery via colonoscopy, and lower number of episodes before FMT. Serious adverse events were uncommon, occurring in 4.7 percent of recipients [<a href="#rid70">70</a>]. Prospective, controlled trials of FMT for<em> C. difficile </em>infection have not been performed in children.</p><p></p><p class="bulletIndent2">A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnaspghan.org%2Ffiles%2FFecal_Microbiota_Transplantation_for_Recurrent.25.pdf&amp;token=ZFNNpdFQZhJYwjYuE%2FM1iXWMFp9FJveIzPNkFwxRJC73V91RnWIwyQszgqL43VTcXht%2FU2jhmz%2F8pcuugF%2Bc1fN4iqAf2OUuGY1nxoGf6Rg4JnxKKeCO%2FSEU%2FEP5czRH&amp;TOPIC_ID=6050" target="_blank">joint position paper</a> from North American and European Pediatric Gastroenterology organizations provides guidance on the use of FMT for recurrent<em> C. difficile</em> infection in children [<a href="#rid69">69</a>]. Given the many clinical and regulatory issues, FMT should only be performed at established centers with experience with FMT. An <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fascopubs.org%2Fdoi%2Fpdfdirect%2F10.1200%2FJCO.18.00407&amp;token=H9BpLdmS%2BpcKxEFYAaP5KvfidZtcp4CzJgIV2aFjht5P0CnYa1uPi8GpKz7dkEuxS47Y%2B9lHm1pRDmTBclVEiA%3D%3D&amp;TOPIC_ID=6050" target="_blank">international multidisciplinary panel of experts</a> in pediatric oncology and infectious diseases recommends against FMT for the treatment <em>of C. difficile</em> infection in children and adolescents with cancer and those who have received hematopoietic cell transplantation [<a href="#rid16">16</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p></p><p class="bulletIndent2">FMT is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2604.html" rel="external">"Fecal microbiota transplantation for treatment of <i>Clostridioides difficile</i> infection"</a>.)</p><p></p><p class="headingAnchor" id="H12961978"><span class="h1">ALTERNATIVE THERAPIES</span><span class="headingEndMark"> — </span>Several alternatives to antimicrobial therapy for <em>C. difficile</em> infection are being investigated, including toxin binding agents, intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a>, and probiotics.</p><p>We suggest not using these therapies for the treatment of children with <em>C. difficile</em> infection because their efficacy and safety have not been established. An <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fascopubs.org%2Fdoi%2Fpdfdirect%2F10.1200%2FJCO.18.00407&amp;token=H9BpLdmS%2BpcKxEFYAaP5KvfidZtcp4CzJgIV2aFjht5P0CnYa1uPi8GpKz7dkEuxS47Y%2B9lHm1pRDmTBclVEiA%3D%3D&amp;TOPIC_ID=6050" target="_blank">international multidisciplinary panel of experts</a> in pediatric oncology and infectious diseases also suggests that these therapies not be used for the treatment of <em>C. difficile</em> infection in children and adolescents with cancer and those who have received hematopoietic cell transplantation [<a href="#rid16">16</a>].</p><p>The alternative therapies are discussed separately. (See  <a class="medical medical_review" href="/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention", section on 'Alternative therapies'</a>.)</p><p class="headingAnchor" id="H2258183282"><span class="h1">PREVENTION OF RECURRENCE</span><span class="headingEndMark"> — </span>Patients remain vulnerable to recurrence for many weeks following treatment of <em>C. difficile</em> infection. During this period of vulnerability, the following preventive measures may reduce the risk of recurrence:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of antimicrobial treatment; if antimicrobial treatment is necessary in a high-risk patient, we suggest tailoring therapy to achieve the narrowest spectrum and shortest duration possible [<a href="#rid7">7</a>] (see <a class="local">'Discontinuation of inciting antibiotics'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Following proper hand hygiene with close attention to environmental cleaning, particularly where toileting and diaper changing occur (see  <a class="medical medical_review" href="/d/html/2687.html" rel="external">"<i>Clostridioides difficile</i> infection: Prevention and control", section on 'Hand hygiene'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of gastric acid suppression (ie, proton pump inhibitors and histamine-2 receptor antagonists) [<a href="#rid71">71</a>] (see  <a class="medical medical_review" href="/d/html/6041.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Microbiology, pathogenesis, and epidemiology", section on 'Other risk factors'</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Most children with <em>C. difficile</em> infection recover without sequelae [<a href="#rid2">2,48,72</a>]. However, among hospitalized children, <em>C. difficile</em> infection is associated with increased in-hospital mortality, length of stay, and hospital cost [<a href="#rid73">73</a>]. In a multicenter cohort of 7318 children hospitalized with <em>C. difficile</em> infection during 2006 through 2011, the 30-day all-cause mortality rate was 1.5 percent; risk factors for death included older age, gastric acid suppression, select chronic conditions (malignancy, cardiovascular disease, hematology/immunologic conditions), and more severe underlying illness [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H23"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The prevention of <em>C. difficile </em>infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/2687.html" rel="external">"<i>Clostridioides difficile</i> infection: Prevention and control"</a>.)</p><p class="headingAnchor" id="H2826465235"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110248.html" rel="external">"Society guideline links: <i>Clostridioides difficile</i> infection"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discontinue inciting antibiotics (preferred) or modify antimicrobial therapy to achieve the narrowest spectrum and shortest duration possible. (See <a class="local">'Discontinuation of inciting antibiotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Correct fluid losses and electrolyte imbalances. (See <a class="local">'Supportive care'</a> above and  <a class="medical medical_review" href="/d/html/6142.html" rel="external">"Clinical assessment of hypovolemia (dehydration) in children"</a> and  <a class="medical medical_review" href="/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hospitalization may be warranted for children with (see <a class="local">'Indications for hospitalization'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Dehydration</p><p class="bulletIndent3"><span class="glyph">-</span>Moderate to marked toxicity</p><p class="bulletIndent3"><span class="glyph">-</span>Severe or fulminant disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Poor access to follow-up care</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for antimicrobial therapy</strong> – We initiate antimicrobial therapy in children with documented symptomatic <em>C. difficile</em> infection (<a class="graphic graphic_table graphicRef71790" href="/d/graphic/71790.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">Empiric antimicrobial therapy may be warranted if there is a delay in laboratory confirmation or for severe or fulminant disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial therapy for initial episode</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild or moderate disease – For children and adolescents with mild or moderate <em>C. difficile</em> disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>), we suggest oral <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a>, or <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">fidaxomicin</a> (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Mild or moderate disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe disease – For children and adolescents with severe <em>C. difficile</em> disease (<a class="graphic graphic_table graphicRef100705" href="/d/graphic/100705.html" rel="external">table 1</a>), we suggest oral <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> as the initial drug of choice (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Severe disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fulminant disease – For children and adolescents with fulminant <em>C. difficile</em> disease, we suggest the combination of intravenous <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> and either oral or rectal <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> (for children unable to tolerate oral therapy) (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Fulminant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to treatment</strong> – We assess the response to treatment for <em>C. difficile</em> infection clinically. Symptoms generally improve within 48 to 72 hours after initiation of antibiotic therapy, but diarrhea may not fully resolve for four to five days. We do not obtain follow-up stool studies. (See <a class="local">'Response to treatment'</a> above.)</p><p></p><p class="bulletIndent1">Progression of disease while on treatment or failure to improve after several days of therapy defines treatment failure. Treatment failure is uncommon in children. Children with treatment failure should be evaluated (or reevaluated) for other causes of diarrhea. (See  <a class="medical medical_review" href="/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis", section on 'Differential diagnosis'</a> and <a class="local">'Management of treatment failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of recurrence</strong> – Recurrence of <em>C. difficile</em> infection after completion of antibiotic treatment may represent a relapse of the previous infecting strain or reinfection with a new strain. (See <a class="local">'Management of recurrence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial recurrence – For the first recurrence <em>of C. difficile</em> infection in children, we suggest a second course of treatment with the same regimen used for the initial episode (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subsequent recurrences – For children with subsequent recurrences of <em>C. difficile</em> infection, we suggest pulse-tapered oral <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> or oral <a class="drug drug_pediatric" data-topicid="126625" href="/d/drug information/126625.html" rel="external">fidaxomicin</a> (<a class="graphic graphic_table graphicRef117235" href="/d/graphic/117235.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Management of recurrence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of recurrence</strong> – Patients remain vulnerable to recurrent infection for many weeks following treatment for <em>C. difficile</em> infection. Avoid antibiotics if possible during the period of vulnerability. (See <a class="local">'Prevention of recurrence'</a> above.)</p><p></p><p class="headingAnchor" id="H33"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Cooperstock, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825.</a></li><li><a class="nounderline abstract_t">Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122:1266.</a></li><li><a class="nounderline abstract_t">Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011; 165:451.</a></li><li><a class="nounderline abstract_t">Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010; 16:604.</a></li><li><a class="nounderline abstract_t">Deshpande A, Pant C, Anderson MP, et al. Clostridium difficile infection in the hospitalized pediatric population: increasing trend in disease incidence. Pediatr Infect Dis J 2013; 32:1138.</a></li><li class="breakAll">American Academy of Pediatrics. Clostridioides difficile (formerly Clostridium difficile). In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.271.</li><li><a class="nounderline abstract_t">McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66:e1.</a></li><li><a class="nounderline abstract_t">Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021; 116:1124.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Clostridioides difficile infection: antimicrobial prescribing. https://www.nice.org.uk/guidance/ng199 (Accessed on February 08, 2022).</li><li><a class="nounderline abstract_t">Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440.</a></li><li><a class="nounderline abstract_t">Tschudin-Sutter S, Tamma PD, Milstone AM, Perl TM. Predictors of first recurrence of Clostridium difficile infections in children. Pediatr Infect Dis J 2014; 33:414.</a></li><li><a class="nounderline abstract_t">Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340:c1296.</a></li><li><a class="nounderline abstract_t">Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48:598.</a></li><li><a class="nounderline abstract_t">Vasa CV, Glatt AE. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. Am J Gastroenterol 2003; 98:354.</a></li><li><a class="nounderline abstract_t">Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297.</a></li><li><a class="nounderline abstract_t">Diorio C, Robinson PD, Ammann RA, et al. Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. J Clin Oncol 2018; 36:3162.</a></li><li><a class="nounderline abstract_t">Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis 2013; 56:1401.</a></li><li><a class="nounderline abstract_t">Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe clostridium difficile infection in children. Pediatr Infect Dis J 2012; 31:134.</a></li><li><a class="nounderline abstract_t">Parmar D, Dang R, Miranda-Katz M, et al. Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children. Pediatr Infect Dis J 2019; 38:1073.</a></li><li><a class="nounderline abstract_t">Tashiro S, Mihara T, Okawa R, et al. Optimal therapeutic recommendation for Clostridioides difficile infection in pediatric and adolescent populations: a systematic review and meta-analysis. Eur J Pediatr 2023; 182:2673.</a></li><li><a class="nounderline abstract_t">Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302.</a></li><li><a class="nounderline abstract_t">Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59:345.</a></li><li><a class="nounderline abstract_t">Wenisch C, Parschalk B, Hasenhündl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813.</a></li><li><a class="nounderline abstract_t">Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043.</a></li><li><a class="nounderline abstract_t">Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 2017; 3:CD004610.</a></li><li><a class="nounderline abstract_t">Wolf J, Kalocsai K, Fortuny C, et al. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). Clin Infect Dis 2020; 71:2581.</a></li><li><a class="nounderline abstract_t">Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021; 73:e1029.</a></li><li><a class="nounderline abstract_t">Stevens VW, Khader K, Echevarria K, et al. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci. Clin Infect Dis 2020; 71:645.</a></li><li><a class="nounderline abstract_t">Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169.</a></li><li><a class="nounderline abstract_t">Baines SD, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62:1046.</a></li><li><a class="nounderline abstract_t">Peláez T, Alcalá L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46:1647.</a></li><li><a class="nounderline abstract_t">Kociolek LK, Gerding DN, Osmolski JR, et al. Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients. Antimicrob Agents Chemother 2016; 60:4896.</a></li><li><a class="nounderline abstract_t">O'Gorman MA, Michaels MG, Kaplan SL, et al. Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial. J Pediatric Infect Dis Soc 2018; 7:210.</a></li><li class="breakAll">Dificid (fidaxomicin) for oral use. US Food and Drug Administration (FDA) approved product information. Revised January 2020. US Food and Drug Administration. (Available online at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm, accessed February, 2020.).</li><li><a class="nounderline abstract_t">Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586.</a></li><li><a class="nounderline abstract_t">Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591.</a></li><li><a class="nounderline abstract_t">Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5:549.</a></li><li><a class="nounderline abstract_t">Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372:1539.</a></li><li><a class="nounderline abstract_t">Wood A, Wassil K, Edwards E. Oral Absorption of Enteral Vancomycin in a Child with Clostridium difficile Colitis and Renal Impairment. J Pediatr Pharmacol Ther 2013; 18:315.</a></li><li><a class="nounderline abstract_t">Wenisch JM, Schmid D, Kuo HW, et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2012; 56:1974.</a></li><li><a class="nounderline abstract_t">Saffouri G, Khanna S, Estes L, Pardi D. Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection. Am J Gastroenterol 2014; 109:924.</a></li><li><a class="nounderline abstract_t">Lee J, Tashjian DB, Moriarty KP. Is partial colectomy the operation of choice in pediatric Clostridium difficile colitis? Pediatr Surg Int 2012; 28:603.</a></li><li><a class="nounderline abstract_t">Castillo A, López J, Panadero E, et al. Conservative surgical treatment for toxic megacolon due to Clostridium difficile infection in a transplanted pediatric patient. Transpl Infect Dis 2012; 14:E34.</a></li><li><a class="nounderline abstract_t">Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984; 6 Suppl 1:S235.</a></li><li><a class="nounderline abstract_t">Al-Nassir WN, Sethi AK, Nerandzic MM, et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47:56.</a></li><li><a class="nounderline abstract_t">Yin J, Kociolek LK, Same RG, et al. Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridiodes difficile Infections. Open Forum Infect Dis 2019; 6:ofz492.</a></li><li><a class="nounderline abstract_t">Kociolek LK, Patel SJ, Shulman ST, Gerding DN. Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort study. Infect Control Hosp Epidemiol 2015; 36:445.</a></li><li><a class="nounderline abstract_t">Schwartz KL, Darwish I, Richardson SE, et al. Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study. BMC Pediatr 2014; 14:28.</a></li><li><a class="nounderline abstract_t">Crews JD, Koo HL, Jiang ZD, et al. A hospital-based study of the clinical characteristics of Clostridium difficile infection in children. Pediatr Infect Dis J 2014; 33:924.</a></li><li><a class="nounderline abstract_t">Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758.</a></li><li><a class="nounderline abstract_t">McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28:140.</a></li><li><a class="nounderline abstract_t">Sammons JS, Gerber JS, Tamma PD, et al. Diagnosis and Management of Clostridium difficile Infection by Pediatric Infectious Diseases Physicians. J Pediatric Infect Dis Soc 2014; 3:43.</a></li><li><a class="nounderline abstract_t">Tamma PD, Sandora TJ. Clostridium difficile Infection in Children: Current State and Unanswered Questions. J Pediatric Infect Dis Soc 2012; 1:230.</a></li><li><a class="nounderline abstract_t">Hota SS, Sales V, Tomlinson G, et al. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial. Clin Infect Dis 2017; 64:265.</a></li><li><a class="nounderline abstract_t">Sirbu BD, Soriano MM, Manzo C, et al. Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis 2017; 65:1396.</a></li><li><a class="nounderline abstract_t">McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769.</a></li><li><a class="nounderline abstract_t">Patron RL, Hartmann CA, Allen S, et al. Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis 2017; 65:1214.</a></li><li><a class="nounderline abstract_t">Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 2017; 376:305.</a></li><li><a class="nounderline abstract_t">Sferra TJ, Merta T, Neely M, et al. Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III). J Pediatric Infect Dis Soc 2023; 12:334.</a></li><li><a class="nounderline abstract_t">Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005; 3:201.</a></li><li><a class="nounderline abstract_t">Mattila E, Arkkila P, Mattila PS, et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013; 37:122.</a></li><li><a class="nounderline abstract_t">Patrick Basu P, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 2010; 3:221.</a></li><li><a class="nounderline abstract_t">Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48:425.</a></li><li><a class="nounderline abstract_t">Miller MA, Blanchette R, Spigaglia P, et al. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol 2011; 49:4319.</a></li><li><a class="nounderline abstract_t">Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996; 40:2266.</a></li><li><a class="nounderline abstract_t">Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43:421.</a></li><li><a class="nounderline abstract_t">Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009; 48:e41.</a></li><li><a class="nounderline abstract_t">Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; 59:705.</a></li><li><a class="nounderline abstract_t">Davidovics ZH, Michail S, Nicholson MR, et al. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2019; 68:130.</a></li><li><a class="nounderline abstract_t">Nicholson MR, Mitchell PD, Alexander E, et al. Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. Clin Gastroenterol Hepatol 2020; 18:612.</a></li><li><a class="nounderline abstract_t">Tariq R, Singh S, Gupta A, et al. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med 2017.</a></li><li><a class="nounderline abstract_t">Pai S, Aliyu SH, Enoch DA, Karas JA. Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PLoS One 2012; 7:e51728.</a></li><li><a class="nounderline abstract_t">Sammons JS, Localio R, Xiao R, et al. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis 2013; 57:1.</a></li><li><a class="nounderline abstract_t">Vendetti N, Zaoutis T, Coffin SE, Sammons JS. Risk factors for in-hospital mortality among a cohort of children with Clostridium difficile infection. Infect Control Hosp Epidemiol 2015; 36:1183.</a></li></ol></div><div id="topicVersionRevision">Topic 6050 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25714160" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Burden of Clostridium difficile infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047244" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21199971" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clostridium difficile infection in hospitalized children in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20350373" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clostridium difficile infections among hospitalized children, United States, 1997-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23546535" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clostridium difficile infection in the hospitalized pediatric population: increasing trend in disease incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23546535" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clostridium difficile infection in the hospitalized pediatric population: increasing trend in disease incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29462280" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34003176" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34003176" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844027" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24168983" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predictors of first recurrence of Clostridium difficile infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20228142" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevention and medical management of Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19191646" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591054" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1322075" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30216124" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408679" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The epidemiology of Clostridium difficile infection in children: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22031485" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk factors and outcomes associated with severe clostridium difficile infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31626042" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37000258" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Optimal therapeutic recommendation for Clostridioides difficile infection in pediatric and adolescent populations: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599306" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24799326" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722937" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6138597" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28257555" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31773143" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34164674" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504328" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3781329" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18693234" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Emergence of reduced susceptibility to metronidazole in Clostridium difficile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12019070" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27270275" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28575523" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28575523" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15889354" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15889355" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16122678" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of Clostridium difficile-associated disease: old therapies and new strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25875259" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719593" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Oral Absorption of Enteral Vancomycin in a Child with Clostridium difficile Colitis and Renal Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22252830" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24896763" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22543511" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Is partial colectomy the operation of choice in pediatric Clostridium difficile colitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22726419" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Conservative surgical treatment for toxic megacolon due to Clostridium difficile infection in a transplanted pediatric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6718937" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of antibiotic-associated pseudomembranous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18491964" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31950069" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridiodes difficile Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25782900" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24485120" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25361022" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A hospital-based study of the clinical characteristics of Clostridium difficile infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16477549" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17265394" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Recommendations for surveillance of Clostridium difficile-associated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26624906" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diagnosis and Management of Clostridium difficile Infection by Pediatric Infectious Diseases Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687578" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clostridium difficile Infection in Children: Current State and Unanswered Questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011612" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28591789" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12135033" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28575220" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28121498" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37389891" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15918778" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23095030" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rifaximin in the treatment of recurrent Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21180604" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19140738" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998414" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8891127" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16838229" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Nitazoxanide for the treatment of Clostridium difficile colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19133801" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17337513" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30540704" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31009795" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28346595" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23300561" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532470" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135055" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Risk factors for in-hospital mortality among a cohort of children with Clostridium difficile infection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
